Skip to main content
All lobbying filings

The Petrizzo Group, Inc.

The Petrizzo Group, Inc. filed a Q3 report for Akebia Therapeutics, Inc. on October 15, 2026, reporting $60,000 in lobbying income.

Lobbying for Akebia Therapeutics, Inc. · Fully integrated biopharmaceutical company addressing complications of kidney disease.

As filed: THE PETRIZZO GROUP, INC. for AKEBIA THERAPEUTICS, INC.

All filings by The Petrizzo Group, Inc. · Everything Akebia Therapeutics, Inc. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 15, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Health Issues

Provided legislative advocacy specific to the payment of innovative drugs, such as phosphate binders and anemia management drugs in the Medicare End-Stage Renal Dialysis Prospective Payment System (ESRD PPS).

Medicare/Medicaid

Provided legislative advocacy specific to the payment of innovative drugs, such as phosphate binders and anemia management drugs in the Medicare End-Stage Renal Dialysis Prospective Payment System (ESRD PPS).

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem